RNA-Guided Genomic Localization of H2A.L.2 Histone Variant.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
18 02 2020
Historique:
received: 31 01 2020
revised: 14 02 2020
accepted: 16 02 2020
entrez: 23 2 2020
pubmed: 23 2 2020
medline: 20 2 2021
Statut: epublish

Résumé

The molecular basis of residual histone retention after the nearly genome-wide histone-to-protamine replacement during late spermatogenesis is a critical and open question. Our previous investigations showed that in postmeiotic male germ cells, the genome-scale incorporation of histone variants TH2B-H2A.L.2 allows a controlled replacement of histones by protamines to occur. Here, we highlight the intrinsic ability of H2A.L.2 to specifically target the pericentric regions of the genome and discuss why pericentric heterochromatin is a privileged site of histone retention in mature spermatozoa. We observed that the intranuclear localization of H2A.L.2 is controlled by its ability to bind RNA, as well as by an interplay between its RNA-binding activity and its tropism for pericentric heterochromatin. We identify the H2A.L.2 RNA-binding domain and demonstrate that in somatic cells, the replacement of H2A.L.2 RNA-binding motif enhances and stabilizes its pericentric localization, while the forced expression of RNA increases its homogenous nuclear distribution. Based on these data, we propose that the specific accumulation of RNA on pericentric regions combined with H2A.L.2 tropism for these regions are responsible for stabilizing H2A.L.2 on these regions in mature spermatozoa. This situation would favor histone retention on pericentric heterochromatin.

Identifiants

pubmed: 32085641
pii: cells9020474
doi: 10.3390/cells9020474
pmc: PMC7072763
pii:
doi:

Substances chimiques

Heterochromatin 0
Histones 0
RNA Recognition Motif Proteins 0
RNA, Nuclear 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Nat Struct Mol Biol. 2012 Nov;19(11):1076-83
pubmed: 23085713
Mol Cell. 2012 Jan 27;45(2):147-57
pubmed: 22284675
Curr Biol. 2000 Nov 30;10(23):1531-4
pubmed: 11114523
Nat Struct Mol Biol. 2013 Nov;20(11):1321-4
pubmed: 24096363
Cell Chem Biol. 2019 Oct 17;26(10):1436-1449.e5
pubmed: 31447351
Mol Cell Biol. 2006 Feb;26(3):1156-64
pubmed: 16428466
Dev Cell. 2010 Oct 19;19(4):625-38
pubmed: 20951352
Nat Struct Mol Biol. 2011 Dec 04;19(1):25-30
pubmed: 22139013
Nucleic Acids Res. 2009 Aug;37(14):4684-95
pubmed: 19506029
Mol Cell Biol. 2009 Jan;29(1):150-6
pubmed: 18936163
Sci Rep. 2013 Dec 16;3:3510
pubmed: 24336483
Dev Cell. 2016 Apr 4;37(1):98-104
pubmed: 27046835
Cell Rep. 2018 Jun 26;23(13):3920-3932
pubmed: 29949774
Nature. 2009 Jul 23;460(7254):473-8
pubmed: 19525931
J Cell Biol. 2007 Jan 29;176(3):283-94
pubmed: 17261847
Genes Dev. 2013 Aug 1;27(15):1680-92
pubmed: 23884607
EMBO J. 2004 Aug 18;23(16):3314-24
pubmed: 15257289
EMBO J. 2012 Oct 3;31(19):3809-20
pubmed: 22922464
Cell Rep. 2018 Sep 25;24(13):3477-3487.e6
pubmed: 30257209
Nat Commun. 2018 Sep 24;9(1):3885
pubmed: 30250204
Nat Struct Mol Biol. 2013 Jul;20(7):868-75
pubmed: 23770822
Nat Struct Mol Biol. 2010 Jun;17(6):679-87
pubmed: 20473313
Cell. 2014 Jul 3;158(1):98-109
pubmed: 24995981
Mol Cell. 2016 Apr 21;62(2):169-180
pubmed: 27105113
Dev Cell. 2014 Jul 14;30(1):23-35
pubmed: 24998597
Genome Res. 2018 Apr;28(4):460-473
pubmed: 29549088
Genes Dev. 2016 Mar 15;30(6):611-21
pubmed: 26980186
Dev Cell. 2014 Jul 14;30(1):6-8
pubmed: 25026032
PLoS Genet. 2017 Feb 24;13(2):e1006633
pubmed: 28234895
Mol Cell. 2017 Apr 6;66(1):89-101.e8
pubmed: 28366643
Dev Cell. 2014 Jul 14;30(1):11-22
pubmed: 24998598

Auteurs

Naghmeh Hoghoughi (N)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Sophie Barral (S)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Sandrine Curtet (S)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Florent Chuffart (F)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Guillaume Charbonnier (G)

TGML, platform IbiSA, Aix Marseille Univ, Inserm U1090, TAGC, 13288 Marseille, France.

Denis Puthier (D)

TGML, platform IbiSA, Aix Marseille Univ, Inserm U1090, TAGC, 13288 Marseille, France.

Thierry Buchou (T)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Sophie Rousseaux (S)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Saadi Khochbin (S)

CNRS UMR 5309, Inserm, U1209, Université Grenoble Alpes, Institute for Advanced Biosciences, F-38700 Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH